A Phase 2, Multiple Centers, Double-blind, Placebo-Controlled, Randomised Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.
Latest Information Update: 09 Nov 2022
At a glance
- Drugs HS 20004 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 04 Nov 2022 Status changed from not yet recruiting to completed.
- 28 Feb 2019 New trial record